The only thing I can figure regarding today's price action is concern that NGVC will post results that may mirror those of Whole Foods' results announced yesterday. Either that or there was a leak of the quarterly results.
It's good to see some recent insider buying by new CEO Van Kirk as well as Swenson and Cabillot. Hopefully, this is an indication that PDEX will be back in the black in the June 4th quarter.
Maybe Mike Davis can apologize to Andy Jacobson and get him to come back. He dug the company out the pits in a short period his last time around but was shoved out for no apparent reason by Gregg Robertson and David Rosenthal.
Why doesn't Mr. Saraf explain in his proxy letter how he manipulated the stock just before he exercised his options a few weeks ago. He announced a large dividend which gave a quick boost to the stock, then exercised his options, sold a portion of the stock to pay for the stock he purchased at the inflated price PLUS collected the dividend that he initiated. This guy needs to be reigned in. Voting for the Erikson proposal is a good start.
I'm trying to figure out why when the company earned $0.24 per share last quarter that the earnings estimate for this quarter is only $0.15. Can anyone (with any analytical skills) help me with this?
I agree with southwalled regarding the BOD. This company has never had any decent board direction or oversite, but have (until just recently with their astaxanthin) produced very good products, and their spirulina is by far the best in the industry. The sales growth for spirulina looks outstanding in both bulk and branded, and I hope they don't neglect this product at the expense of astaxanthin. But I do hope they've finally got it right and can start firing on all cylinders, because they've rocketed up their overhead to the point where they'll have difficulty surviving another major screw up.
ohcguy, do you actually use astaxanthin?
I can't teach you how to read, but today's press release has three mentions of how the company is attempting to improve the quality of the product. If there's not a quality issue, then why try to improve it? Why hire two high level employees if there's no need?
As far as your assumptions, I have substantial stock holdings in the company and have been a stockholder since the early 90's. I have no affiliation with Valensa.
Had they not started the fight with Valensa and continued to work with them they would never had an issue with the extraction (Valensa did a good job) nor would they have had to fight a lawsuit, and how different things would look now! Arrogance gets you nowhere, Mr. Bailey.
Unfortunately, I don't think the first quarter will be any better than the fourth. I would opine that the New Zealand extraction set-up has been a fiasco that they (management) have played down. They repeatedly mentioned quality issues and this has obviously been going on for quite a while, and in my experience has negatively affected the quality of the end product. This is extremely unfortunate, because users are not experiencing the positive effects of the astaxanthin that they would otherwise be experiencing. Fortunately, with the new equipment this issue should be behind them and product quality should improve immensely, however, all the marketing efforts over the past few years have been wasted on a less than quality product that I would guess is still on the shelves at this point, and I don't think that consumers are going to want to repurchase a product that doesn't provide the intended benefits.
Think about what you're saying Alex. So if there's a disagreement between the auditors and management, who would you usually place more trust in? Certainly not the people brought in by the prior board chairman Gregg Robertson & CEO Rosenthau.
Why would a CEO want to destroy his own as well as his company's credibility? I guess if your claim to fame is selling Calcium Carbonate and Magnesium Oxide, you may not have had any to begin with.
Hopefully, Saraf will announce his retirement as well. I'm planning on voting with the Erikson group. This latest episode should be the last time Saraf has a chance to screw SODI shareholders.
I'm betting they'll file another extension. Bailey's setting himself up for a shareholder lawsuit. It's not wise to play games of this sort.
$10 million (or 20%) of lost market capitalization due to the delayed annual report filing. I wouldn't be singing Bailey's praises. He's done nothing yet. The OZ/Mercola story spurred demand and Bailey did nothing to supply it with a quality product. I had to switch brands after many years of use because of lost efficacy. I'm hoping that the in-house extraction will fix the problems with the New Zealand extraction shortcomings before consumers realize what has been going on.
It looks like Deal exercised 5000 options at $3.82 in March. Kudos to her. I don't see any such activity in regard to Bailey, but why should he exercise unless his options are nearing expiration?
I think there's more than we'll ever know to this delayed earnings announcement, and we could speculate to no end, but if there's an issue with signing off on disclosures, then I think the Board needs to take some action regarding Mr. Bailey. His lack of communication with shareholders is going to breed mis-trust. Coming from the company that produces Nature Made (cheap worthless junk as far as I'm concerned) vitamins doesn't give me a warm, fuzzy feeling to begin with. And by the way, this delay has cost us over $8 million dollars in market capitalization, so how much in added expense would they have had to incur to make the earning announcement on time?